





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/690,454	10/18/2000	Steven M. Ruben	PZ006P1C1	1914
22195	7590 09/27/2002			•
	NOME SCIENCES I	EXAMINER		
ROCKVILLE	EST AVENUE , MD 20850		CARLSON, KAREN C	
			ART UNIT	PAPER NUMBER
			1653	111
			DATE MAILED: 09/27/2002	174

Please find below and/or attached an Office communication concerning this application or proceeding.

12 1						
	Application No.	Applicant(s)				
Office Action Summary	09/690,454	RUBEN ET AL.				
Office Action Summary	Examiner	Art Unit				
The MAILING DATE of this communication and	Karen Cochrane Carlson, Ph.D.	1653				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on 26.	July 2002 .					
2a)⊠ This action is <b>FINAL</b> . 2b)□ Th	nis action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) 1,13 and 17-75 is/are pending in the application.						
4a) Of the above claim(s) 1,13 and 17-24 is/are withdrawn from consideration.						
5) Claim(s) <u>25-36</u> is/are allowed.						
6)⊠ Claim(s) <u>37-75</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) acce						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority document	ts have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 09/690,454

Art Unit: 1653

This Office is in response to Paper #13, filed July 26, 2002. Claims 2-12, and 14-16 have been canceled. Claims 1, 13, and 17-24 have been withdrawn from further consideration by the Examiner because these Claims are drawn to non-elected Inventions. Claims 25-76 are currently under examination.

## Withdrawal of Rejections:

The rejection of Claims 25-76 under 35 U.S.C. 101 is withdrawn.

The rejection of Claims 25-76 under 35 U.S.C. 112, first paragraph is withdrawn.

The rejection of Claims 37-76 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, is withdrawn.

## **New Rejection Necessitated by Amendments**

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 37-75 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These Claims have been amended to recite that a first a polypeptide is able to generate an antibody specific to a second polypeptide. Using Claim 37 as an example, the claimed first polypeptide is at least 90% identical to a second polypeptide comprising amino acid sequence 30-113 of SEQ ID NO: 59, and it's function is to generate an antibody that specifically binds to this second second polypeptide. The second polypeptide comprises the sequence 30-113 of SEQ ID NO:59 and is not limited to these amino acids and therefore the

Art Unit: 1653

antibody specificity is indefinite. Further, one polypeptide cannot make an antibody that is specific to a second polypeptide. Therefore, the claims are indefinite because the claimed activity is not art-recognized.

This rejection may be overcome by amending the claims to recite the function of the polypeptide. For example: An isolated polypeptide having 90% identity to SEQ ID NO: 2, wherein said polypeptide has angiogenic activity.

Claims 25-36 are allowed.

This application contains claims 1, 13, and 17-24 drawn to an invention nonelected with traverse in Paper No. 9. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 09/690,454

Art Unit: 1653

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 703-308-0034. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 703-308-2329. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

September 25, 2002

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

Kare Cochan Carbon Rit